A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
"HOT PROMO DARI P0KERV1TA untuk para member kami :
* B0nus Referral 20% Seumur Hidup
* Bonus Turn0ver Hariaan 0,5%
* NO ROBOT & ADMIN
* 100% Fair Play Member Vs Member
* Proses Withdraw & Deposit Tercepat
* Customer Service yang baik dan ramah
Contact Us Person :
? LIVECHAT POKERV1TA
? WA: 082312256064
? BBM : D88B0154"